Search results for "ATHEROSCLEROSIS"

showing 10 items of 499 documents

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2020

Abstract: Background Health system planning requires careful assessment of chronic kidney disease (CKD) epidemiology, but data for morbidity and mortality of this disease are scarce or non-existent in many countries. We estimated the global, regional, and national burden of CKD, as well as the burden of cardiovascular disease and gout attributable to impaired kidney function, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. We use the term CKD to refer to the morbidity and mortality that can be directly attributed to all stages of CKD, and we use the term impaired kidney function to refer to the additional risk of CKD from cardiovascular disease and gout. Methods Th…

Systems AnalysisGoutCost effectiveness030204 cardiovascular system & hematologyGlobal HealthGLOMERULAR-FILTRATION-RATEGlobal Burden of DiseaseCOST-EFFECTIVENESS0302 clinical medicineCause of DeathPrevalenceGlobal healthDiabetic NephropathiesRegistries030212 general & internal medicineSUB-SAHARAN AFRICA11 Medical and Health SciencesIncidenceMortality rate1. No povertyGeneral MedicineHälsovetenskaperGBD Chronic Kidney Disease CollaborationCKD-EPI EQUATION3. Good healthEuropeCardiovascular Diseases/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingQuality-Adjusted Life YearsLife Sciences & BiomedicineAsiaOceania195 COUNTRIESATHEROSCLEROSIS RISKCARDIOVASCULAR OUTCOMESRisk AssessmentArticle03 medical and health sciencesMedicine General & InternalSDG 3 - Good Health and Well-beingRISK-FACTORGeneral & Internal MedicineEnvironmental healthHealth SciencesmedicineHumansGBD chronic kidney diseaseMortalityRisk factorRenal Insufficiency ChronicDisease burdenQMScience & TechnologyAustralasiabusiness.industryPERIPHERAL ARTERIAL-DISEASEBayes Theoremmedicine.diseaseHealth SurveysQuality-adjusted life yearRENAL-DISEASELatin AmericaYears of potential life lostAfricaNorth AmericaHuman medicinebusinessRCKidney disease
researchProduct

TFPI antigen and activity levels in patients with asymptomatic atherosclerosis and target organ acute and chronic complications

2005

AIM: In patients with atherosclerosis there is an activation of the tissue factor mediated coagulation cascade. The aim of our study was to ascertain if there is a relationship between increased tissue factor pathway inhibitor (TFPI) antigen and activity plasma levels and atherosclerosis. METHODS: Design: case-control study. Setting: Department of Internal Medicine and Cardiovascular Diseases, University of Palermo and Laboratory of Genetics and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Patients: 63 consecutive patients with asymptomatic atherosclerosis or with its acute or chronic complications, and 20 healthy volunteers. Measurements: TFPI antigen was detected by an immunoenzima…

TFPI Atherosclerosis
researchProduct

Stroke subtypes and their possible implication in stroke prevention drug strategies

2014

Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the…

TOAST ClassificationDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectBlood PressureStroke subtype preventionInternal medicinemedicineAnimalsHumanscardiovascular diseasesStrokeAntihypertensive AgentsRandomized Controlled Trials as Topicmedia_commonPharmacologyAspirinbusiness.industryDipyridamoleAtherosclerosismedicine.diseaseSurgeryStrokeDipyridamoleClinical trialBlood pressureCardiologyCardiology and Cardiovascular MedicineComplicationbusinessLipohyalinosisPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Medical therapy for patients with subclinical and clinical carotid atherosclerosis

2012

The management of carotid artery disease includes both modifications in life style as well treatment of vascular risk factors. However, strict risk factor modification, including improved antihypertensive therapy, lipid management, smoking cessation, and antiplatelet therapy, promise for reducing the vascular event rate in patients with carotid atherosclerosis. The best medical management for stroke prevention was highlighted in clinical practice guidelines issued jointly in 2006 by the American Heart Association and the American Stroke Association, and co-sponsored by the Council on Cardiovascular Radiology and Intervention and the American Academy of Neurology. Lowering blood pressure to …

Therapy atherosclerosis
researchProduct

Ambient Air Pollution and Atherosclerosis: Insights Into Dose, Time, and Mechanisms.

2021

Ambient air pollution due to particulate matter ≤2.5 μ is the leading environmental risk factor contributing to global mortality, with a preponderant majority of these deaths attributable to atherosclerotic cardiovascular disease (ASCVD) causes such as stroke and myocardial infarction. Epidemiological studies in humans have provided refined estimates of exposure risk, with evidence suggesting that risk association with particulate matter ≤2.5 levels and ASCVD continues at levels well below air quality guidelines in North America and Europe. Mechanistic studies in animals and humans have provided a framework of understanding of the duration and pathways by which air pollution exposure may pr…

Time FactorsAir pollution030204 cardiovascular system & hematologymedicine.disease_causeCardiovascular SystemRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsAir PollutionmedicineAnimalsHumans030212 general & internal medicineParticle SizeAir PollutantsAmbient air pollutionDose-Response Relationship DrugEnvironmental ExposureParticulatesAtherosclerosisEnvironmental chemistryEnvironmental Risk FactorEnvironmental scienceParticulate MatterCardiology and Cardiovascular MedicineEnvironmental MonitoringArteriosclerosis, thrombosis, and vascular biology
researchProduct

Worldwide burden of LDL cholesterol: Implications in cardiovascular disease

2020

Abstract Background and aim an increased value of low-density lipoprotein cholesterol (LDL-C) is now universally considered a major cardiovascular disease (CVD) risk factor. LDL-C is included in the vast majority of worldwide cardiovascular risk prediction algorithms, as well as in the guidelines for cardiovascular risk prevention. We aimed to provide an overview of the worldwide adverse healthcare impact of low-density lipoprotein cholesterol (LDL-C). Methods and results Data on the epidemiologic burden of LDL-C >1.3 mmol/L were retrieved from Global Health Data Exchange (GHDx) registry. The current burden is 94.92 million disability-adjusted life years (DALYs), with an exponential increas…

Time FactorsDatabases FactualHealth StatusEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030209 endocrinology & metabolismDisease030204 cardiovascular system & hematologyGlobal HealthRisk Assessment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsEnvironmental healthHealth careGlobal healthHumansMedicineRegistriesRisk factorEpidemicsAtherosclerosis; Cardiovascular disease; Cholesterol; Low-density lipoproteinsDyslipidemiasLdl cholesterolNutrition and Dieteticsbusiness.industryCholesterolCholesterol LDLAtherosclerosisCardiovascular diseaseUp-RegulationPrediction algorithmsCholesterolchemistryCardiovascular DiseasesLow-density lipoproteinslipids (amino acids peptides and proteins)Risk preventionQuality-Adjusted Life YearsCardiology and Cardiovascular MedicinebusinessBiomarkersNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Regulation of NOS expression in vascular diseases

2020

Nitric oxide synthases (NOS) are the major sources of nitric oxide (NO), a small bioactive molecule involved in the regulation of many cellular processes. One of the most prominent functions of NO is regulation of vasodilatation and thereby control of blood pressure. Most important for vascular tone is NOS3. Endothelial NOS3-generated NO diffuses into the vascular smooth muscle cells, activates the soluble guanylate cyclase resulting in enhanced cGMP concentrations and smooth muscle cell relaxation. However, more and more evidence exist that also NOS1 and NOS2 contribute to vascular function. We summarize the current knowledge about the regulation of NOS expression in the vasculature by tra…

Vascular smooth muscleNitric Oxide Synthase Type IIINOS1CellNitric Oxide Synthase Type IIBlood PressureVasodilationInflammationNitric Oxide Synthase Type INitric OxideMuscle Smooth VascularNitric oxidechemistry.chemical_compoundmedicineAnimalsHumansProtein IsoformsVascular DiseasesRNA Processing Post-TranscriptionalInflammationRegulation of gene expressionInnate immune systemAtherosclerosisImmunity InnateCell biologyGene Expression Regulation Neoplasticmedicine.anatomical_structurechemistryNitric Oxide Synthasemedicine.symptomProtein Processing Post-TranslationalFrontiers in Bioscience-Landmark
researchProduct

New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors

2011

Microsomal triglyceride transfer protein (MTP) is involved in the synthesis of very low density lipoprotein in the liver. Its deficiency results in abetalipoproteinemia. MTP inhibitors target the assembly and secretion of apolipoprotein B-containing lipoproteins. These agents may potentially play a role, alone or in combination, in the treatment of hypercholesterolemia or hypertriglyceridemia. Clinical applications of MTP inhibitors initially focused primarily on high-dose monotherapy in order to produce substantial reductions in LDL-cholesterol levels but these proved to induce significant hepatic steatosis and transaminase elevations. However, likely orphan indications for MTP inhibitors,…

Very low-density lipoproteinApolipoprotein BHypercholesterolemiaFamilial hypercholesterolemiaLipoproteins VLDLPharmacologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type IIchemistry.chemical_compoundMicrosomesDrug DiscoveryClinical endpointHumansMedicineApolipoproteins BHypertriglyceridemiaPharmacologybiologybusiness.industryCholesterolAbetalipoproteinemiamedicine.diseaseAbetalipoproteinemiaBiochemistrychemistryMTP-inhibitors lipids lipoproteins atherosclerosis cardiovascular prevention.biology.proteinlipids (amino acids peptides and proteins)SteatosisCarrier ProteinsbusinessCurrent Pharmaceutical Design
researchProduct

Periodontal treatment on patients with cardiovascular disease : systematic review and meta-analysis

2018

Podeu consultar la versió en castellà del document a: http://hdl.handle.net/2445/153580

Very low-density lipoproteinmedicine.medical_specialtyMalalties periodontalsDisease030204 cardiovascular system & hematologylaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansGeneral DentistryPeriodontal DiseasesOral Medicine and PathologyMalalties cardiovascularsCholesterolbusiness.industryResearch030206 dentistryAtherosclerosis:CIENCIAS MÉDICAS [UNESCO]Confidence intervalClinical trialCardiovascular diseasesOtorhinolaryngologychemistryCardiovascular DiseasesMeta-analysisUNESCO::CIENCIAS MÉDICASEtiologySurgeryPeriodontal diseasebusinessAterosclerosi
researchProduct

Vascular oxidative stress, nitric oxide and atherosclerosis.

2014

In the vascular wall, reactive oxygen species (ROS) are produced by several enzyme systems including NADPH oxidase, xanthine oxidase, uncoupled endothelial nitric oxide synthase (eNOS) and the mitochondrial electron transport chain. On the other hand, the vasculature is protected by antioxidant enzyme systems, including superoxide dismutases, catalase, glutathione peroxidases and paraoxonases, which detoxify ROS. Cardiovascular risk factors such as hypercholesterolemia, hypertension, and diabetes mellitus enhance ROS generation, resulting in oxidative stress. This leads to oxidative modification of lipoproteins and phospholipids, mechanisms that contribute to atherogenesis. In addition, oxi…

Xanthine OxidaseAntioxidantNitric Oxide Synthase Type IIImedicine.medical_treatmentMice TransgenicOxidative phosphorylationNitric Oxide Synthase Type Imedicine.disease_causeNitric OxideCardiovascular SystemAntioxidantsNitric oxideSuperoxide dismutasechemistry.chemical_compoundMiceSuperoxidesmedicineAnimalsHumansXanthine oxidasechemistry.chemical_classificationReactive oxygen speciesGlutathione PeroxidaseNADPH oxidasebiologyAryldialkylphosphataseSuperoxide DismutaseNADPH OxidasesAtherosclerosisCatalaseMitochondriaOxidative StresschemistryBiochemistrybiology.proteinCardiology and Cardiovascular MedicineReactive Oxygen SpeciesOxidative stressAtherosclerosis
researchProduct